Literature DB >> 28649083

Report - Prevalence of hospital acquired Burkholderia cepacia infection and its antimicrobial susceptibility in a Chinese hospital.

Jinju Duan1, Jianbang Kang2, Ting Han3, Yuqin Ma3, Qian Guo1, Yan Song1, Qiang Zhao1, Yan Yang4, Ruiqin Zhang1.   

Abstract

This study aimed to investigate antimicrobial susceptibility of hospital acquired Burkholderia cepacia infection in Shanxi (China) during August 2009 and December 2012. To characterize an emerging nocosomial infection. The medical records of 112 patients that were tested positive for B. cepacia were retrospectively analyzed. The K-B disk diffusion method was used to determine the drug susceptibility of the isolated strains. A hundred and fifty strains of B. cepacia were isolated from 112 patients. The sensitivity rates of B. cepacia to meropenem, imipenem, cotrimoxazole, minocycline and ceftazidime were 65.7%, 14.3%, 76.0%, 68.1% and 74.1%, respectively. All patients suffered from more than two underlying diseases, 89 (79.5%) from another bacterial infection and 92 (82.1%) with indwelling catheter. All patients were given antibiotics, including 62 patients that received carbapenem antibiotics. The average duration of hospitalization before detection of B. cepacia was 31±24 days, after which 65 patients (58.0%) improved, 22 (19.0%) died, 8 (7.1%) quit the therapy, and 17 (15.2%) were discharged after full recovery. The prevalence of hospital acquired B. cepacia infection and drug-resistance in the hospital is reported and risk factor exploration requires further study.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28649083

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  1 in total

1.  Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center.

Authors:  Priscila Dentini; Fernando Augusto Lima Marson; Luciana Cardoso Bonadia; Carmen Sílvia Bertuzzo; Antônio Fernando Ribeiro; Carlos Emílio Levy; José Dirceu Ribeiro
Journal:  Med Microbiol Immunol       Date:  2017-09-30       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.